GEN Exclusives

More »

GEN News Highlights

More »
Nov 20, 2007

Biogen Idec and Neurimmune Therapeutics to Develop Treatments for Alzheimer’s

  • Biogen Idec and Neurimmune Therapeutics entered into an agreement for the worldwide development and commercialization of fully human antibodies for the treatment of Alzheimer’s disease.

    The alliance will focus on the development of antibodies that bind to amyloid beta. Neurimmune will conduct research to identify potential therapeutic antibodies using its Reverse Translational Medicine platform. Biogen Idec will be responsible for the development and commercialization of all products. Neurimmune could receive an aggregate of $380M in upfront and success-based milestone payments as well as a royalty on net sales of any products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?